Universität zu Köln

Griesinger, F., Radke, S., Lueers, A., Deschler-Baier, B., Kimmich, M., Sebastian, M., Schulz, C., Brugger, W., Wiewrodt, R., Pirker, R., Fruh, M., Gautschi, O. and Wolf, J. (2018). Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example. Pneumologie, 72 (11). S. 774 - 782. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Full text not available from this repository.

Abstract

Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) are widely used in non-small cell lung cancer patients harboring activating EGFR mutations. However, resistance mechanisms, particularly the T790M mutation, hamper longer-term therapeutic success of first and second generation EGFR-TKIs. To address this unmet medical need, EGFR-TKIs of the third generation are under clinical development. Relevant clinical efficacy with mainly mild to moderate class-specific side effects has been shown for third-generation EGFR-TKIs. Molecular testing is of major importance in deciding for treatment with third generation EGFR-TKIs. This article elucidates the developmental state of third generation EGFR-TKIs with its focus on Osimertinib, the first and currently the only compound in this class which is approved in Germany. Additionally, the medical importance of molecular diagnosis using tumor tissue and circulating tumor DNA is discussed.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Griesinger, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Radke, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lueers, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Deschler-Baier, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kimmich, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sebastian, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schulz, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brugger, W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wiewrodt, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pirker, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fruh, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gautschi, O. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-167969
DOI:	10.1055/a-0647-9835
Journal or Publication Title:	Pneumologie
Volume:	72
Number:	11
Page Range:	S. 774 - 782
Date:	2018
Publisher:	GEORG THIEME VERLAG KG
Place of Publication:	STUTTGART
ISSN:	1438-8790
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; MUTATION MEDIATES RESISTANCE; RANDOMIZED PHASE-3 TRIAL; 1ST-LINE TREATMENT; OPEN-LABEL; KINASE INHIBITORS; TUMOR SPECIMENS; CHEMOTHERAPY; AZD9291 Multiple languages Respiratory System Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16796